Q-omics provides the consensus-scored RPL32P17 profile across patient tissues and cancer cell-line models. RPL32P17 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPL32P17 is differentially expressed in 2, with the highest sampling consensus in PAAD. Additionally, RPL32P17 RNA expression shows 5,621 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, PAAD, and STAD as cancer lineages where RPL32P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL32P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL32P17 survival associations across molecular data types. RPL32P17 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL32P17 RNA expression–survival associations across cancer types. High RPL32P17 expression shows unfavorable associations in BRCA, KIRC, KICH, CESC, PAAD and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RPL32P17 RNA expression.
This table summarizes RPL32P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL32P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL32P17 shows lower tumor expression in PAAD and higher tumor expression in KIRC. The PAAD box plot shows higher RPL32P17 RNA expression in normal versus tumor tissue (log2 FC = −0.217, t-test p = .043).
This table shows molecular features associated with RPL32P17 in patient tissues and cancer cell lines. In patient samples, RPL32P17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
